Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Moreno

Showing results (111-120 of 167) with videos related to

Pageof 17
Sort By:
Haematologica|February 9, 2018
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE studyAnne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, et al.
Leukemia & Lymphoma|January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studiesJan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
BMJ Open|June 12, 2023
Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group studyZubaid Rafique, Jeffrey Budden, Carol Moreno Quinn, et al.
Haematologica|January 13, 2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Annals of Hematology|May 21, 2021
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE studyRichard Greil, Alessandra Tedeschi, Carol Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension StudyMatthew S Davids, Bryone J Kuss, Peter Hillmen, et al.
Physiological Genomics|April 10, 2014
Characterization of biological pathways associated with a 1.37 Mbp genomic region protective of hypertension in Dahl S ratsAllen W Cowley, Carol Moreno, Howard J Jacob, et al.
Transplantation and Cellular Therapy|April 22, 2023
Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the LiteratureIrene García-Cadenas, Sara Redondo, Albert Esquirol, et al.
Croatian Medical Journal|October 18, 2008
Genetically hypertensive Brown Norway congenic rat strains suggest intermediate traits underlying genetic hypertensionMarijo Bilusić, Carol Moreno, Nadia E Barreto, et al.
Clinical Kidney Journal|February 2, 2023
Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in GermanyRoberto Pecoits-Filho, Keith McCullough, Daniel Muenz, et al.
Pageof 17

Showing results (111-120 of 167) with videos related to

Sort By:
Pageof 17
Haematologica|February 9, 2018
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE studyAnne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, et al.
Leukemia & Lymphoma|January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studiesJan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
BMJ Open|June 12, 2023
Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group studyZubaid Rafique, Jeffrey Budden, Carol Moreno Quinn, et al.
Haematologica|January 13, 2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Annals of Hematology|May 21, 2021
Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE studyRichard Greil, Alessandra Tedeschi, Carol Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2020
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension StudyMatthew S Davids, Bryone J Kuss, Peter Hillmen, et al.
Physiological Genomics|April 10, 2014
Characterization of biological pathways associated with a 1.37 Mbp genomic region protective of hypertension in Dahl S ratsAllen W Cowley, Carol Moreno, Howard J Jacob, et al.
Transplantation and Cellular Therapy|April 22, 2023
Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the LiteratureIrene García-Cadenas, Sara Redondo, Albert Esquirol, et al.
Croatian Medical Journal|October 18, 2008
Genetically hypertensive Brown Norway congenic rat strains suggest intermediate traits underlying genetic hypertensionMarijo Bilusić, Carol Moreno, Nadia E Barreto, et al.
Clinical Kidney Journal|February 2, 2023
Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in GermanyRoberto Pecoits-Filho, Keith McCullough, Daniel Muenz, et al.
Pageof 17